NeoStem

Life Tech Capital reiterated its Strong Buy rating on NeoStem (NYSE: NBS). At the same time, Life Tech left its price target on the company's stock unchanged at $4. In a research report published today, Life Tech states, "While R&D efforts are ongoing in the U.S., especially with their bone...

LifeTech Capital is maintaining its Strong Buy rating and $4 PT on shares of NeoStem, Inc. (NYSE: NBS). “NeoStem has Record $69.8M in Revenues for 2010,” LifeTech Capital writes. “Suzhou Erye Pharmaceuticals accounted for the majority of revenues in 2010 while new business units, including the...